Domain-validated decision logic for optogenetic stimulation parameter selection, including opsin choice, light delivery, pulse protocols, fiber placement, and control conditions
Installer avec Codex ou Claude Copiez ce prompt, collez-le dans Codex, Claude ou un autre assistant, puis laissez-le vérifier la page du skill et l'installer pour vous.
Une commande directe contourne le prompt de vérification. Examinez la source avant de l'exécuter.
Domain-validated decision logic for optogenetic stimulation parameter selection, including opsin choice, light delivery, pulse protocols, fiber placement, and control conditions
domain
cellular-molecular-neuroscience
authors
["Claude (AI-assisted synthesis)"]
version
1.0.0
papers
["Deisseroth, 2015","Fenno, Yizhar & Deisseroth, 2011","Yizhar, Fenno, Davidson, Mogri & Deisseroth, 2011","Mattis et al., 2012","Aravanis et al., 2007"]
dependencies
{"required":["research-literacy"]}
review_status
ai-generated
Optogenetics Protocol Designer
Purpose
Optogenetic protocol design requires domain expertise that a general-purpose programmer would systematically get wrong. Selecting an opsin is not like selecting a software library — it requires understanding photocycle kinetics, ion selectivity, spectral overlap, expression toxicity, and the biophysics of light propagation through neural tissue. A naive approach risks tissue damage from heating, silencing neurons you intended to activate (depolarization block), or producing uninterpretable results from inadequate controls. This skill encodes the decision logic that bridges the gap between "I want to activate neurons" and a rigorous, publishable optogenetic protocol.
When to Use
Designing a new optogenetic experiment from scratch
Selecting an opsin for a specific excitation/inhibition application
Designing proper control conditions for optogenetic experiments
Troubleshooting failed or ambiguous optogenetic manipulations
Research Planning Protocol
Before executing the domain-specific steps below, you MUST:
State the research question — What neural circuit question is this optogenetic manipulation addressing?
Justify the method choice — Why optogenetics (not chemogenetics, lesion, pharmacology)? What alternatives were considered?
Declare expected outcomes — What behavioral/neural changes do you expect from activation/inhibition?
Note assumptions and limitations — What does this approach assume about the circuit? Where could it mislead?
Present the plan to the user and WAIT for confirmation before proceeding.
For detailed methodology guidance, see the research-literacy skill.
⚠️ Verification Notice
This skill was generated by AI from academic literature. All parameters, thresholds, and citations require independent verification before use in research. If you find errors, please open an issue.
Decision Tree: Research Question to Protocol
Step 1: Define the Manipulation Type
Goal
Category
Key Constraint
Drive action potentials with millisecond precision
Excitation (fast)
Need opsin with tau-off < 15 ms
Sustained depolarization / increased excitability
Excitation (tonic)
Step-function opsin or low-frequency pulsed
Silence neurons during a behavioral epoch
Inhibition (sustained)
Need potent inhibitory opsin, manage heating
Brief synaptic suppression
Inhibition (phasic)
Fast inhibitory opsin, short pulses
Bidirectional control in same animal
Dual manipulation
Spectrally separated opsins required
Step 2: Select Opsin Class
Excitatory Opsins (Cation Channels)
Opsin
Peak lambda
Tau-off
Photocurrent
Best For
Key Citation
ChR2 (H134R)
470 nm
~10 ms
Moderate
Standard activation, well-characterized
Boyden et al., 2005; Nagel et al., 2005
ChETA (E123T)
470 nm
~3 ms
Lower
High-frequency spiking (>40 Hz)
Gunaydin et al., 2010
ChrimsonR
630 nm
~15 ms
Moderate
Red-shifted, deep tissue, dual-color
Klapoetke et al., 2014
ChRmine
520-530 nm
~60 ms
Very high
Ultra-sensitive, large volume activation
Marshel et al., 2019
CheRiff
460 nm
~8 ms
~2x ChR2
All-optical electrophysiology
Hochbaum et al., 2014
C1V1(TT)
540 nm
~50 ms
Moderate
Red-shifted, combinatorial experiments
Yizhar et al., 2011
Inhibitory Opsins
Opsin
Peak lambda
Mechanism
Photocurrent
Best For
Key Citation
eNpHR3.0
590 nm
Cl- pump
Low (pump)
Established inhibition, yellow-light
Gradinaru et al., 2010
eArch3.0
520-550 nm
H+ pump
Moderate (pump)
Green-light inhibition
Chow et al., 2010; Mattis et al., 2012
stGtACR2
480 nm
Anion channel
Very high
Most potent somatic inhibition
Mahn et al., 2018
SwiChR++
480 nm
Anion channel (bistable)
Moderate
Sustained inhibition, low light
Berndt et al., 2016
Step-Function Opsins (Bistable)
Opsin
Activation
Deactivation
Tau-off (dark)
Best For
Key Citation
SSFO
Blue (~470 nm)
Yellow (~590 nm)
~29 min
Sustained excitability increase
Yizhar et al., 2011
SOUL
Blue (~470 nm)
Yellow (~590 nm)
~29 min
Transcranial, minimally invasive
Gong et al., 2020
SwiChR++
Blue (~480 nm)
Red (~600 nm)
~115 s
Bistable inhibition
Berndt et al., 2016
See references/opsin-catalog.md for the complete opsin reference with detailed kinetics.
Step 3: Determine Light Parameters
Power Density at Target Tissue
ChR2 EPD50: ~1.3 mW/mm2 (Mattis et al., 2012)
stGtACR2 EPD50: ~0.05 mW/mm2 (Mahn et al., 2018) — 100-200x more sensitive than NpHR
eNpHR3.0 EPD50: ~5-10 mW/mm2 (Mattis et al., 2012)
ChRmine: effective at sub-mW/mm2 levels (Marshel et al., 2019)
Typical working range: 1-10 mW/mm2 for most excitatory opsins at the fiber tip (Aravanis et al., 2007)
CRITICAL — Tissue Heating Threshold:
Temperature increase of ~0.1-0.25 deg C per mW at fiber tip for 473 nm light (Stujenske et al., 2015)
Keep total tissue temperature rise below 1 deg C to avoid artifacts (Christie et al., 2013; Owen et al., 2019)
At 20 mW/mm2, duty cycles above ~40% risk exceeding 1 deg C (Stujenske et al., 2015)
Blue light at high power can alter firing rates even WITHOUT opsin expression (Owen et al., 2019)
Light Attenuation in Tissue
90% of 473 nm light is lost within 1 mm of brain tissue (Aravanis et al., 2007; Yizhar et al., 2011)
At 500 um from fiber tip: ~3.2% of initial intensity remains
At 1 mm from fiber tip: ~0.56% of initial intensity remains
Red-shifted light (>600 nm) penetrates deeper due to lower scattering (Klapoetke et al., 2014)
Wavelength Selection
Match the laser/LED wavelength to the opsin's absorption peak:
Opsin Class
Recommended Wavelength
Common Laser Lines
ChR2 / CheRiff / stGtACR2
450-490 nm
473 nm
C1V1 / ChRmine / eArch3.0
520-560 nm
532 nm, 561 nm
eNpHR3.0
570-600 nm
594 nm
ChrimsonR
600-650 nm
638 nm
See references/stimulation-parameters.md for complete pulse protocol recipes.
Step 4: Design Pulse Protocol
General Principles
Pulse width: 1-10 ms for fast excitatory opsins; 5-25 ms for slower or inhibitory opsins (Mattis et al., 2012)
Frequency: Must not exceed the opsin's temporal fidelity limit
Duty cycle: Balance activation efficacy against heating; keep below 40% for sustained protocols at moderate power (Stujenske et al., 2015)
Ramp-down for inhibition: When ending sustained inhibitory light, ramp down over 500 ms to 1 s to avoid rebound excitation (Mahn et al., 2016)
Frequency Limits by Opsin
Opsin
Max Reliable Spike Rate
Notes
ChR2 (H134R)
~30-40 Hz sustained
Fails above gamma range in sustained trains (Mattis et al., 2012)
ChETA
~100-200 Hz
Reduced photocurrent trade-off (Gunaydin et al., 2010)
ChrimsonR
~20-30 Hz
Slower kinetics than ChR2 (Klapoetke et al., 2014)
ChRmine
~50 Hz (80 Hz with hsChRmine)
Large photocurrent compensates for slower kinetics (Marshel et al., 2019)
Chronos
~100 Hz
Fastest known excitatory opsin (Klapoetke et al., 2014)
Step 5: Fiber Optic Specifications
Parameter
Standard Value
Rationale
Core diameter
200 um (mice), 200-400 um (rats/primates)
Balances illumination volume vs. tissue damage (Aravanis et al., 2007)
Numerical aperture (NA)
0.22 or 0.39
0.22 for focused beam; 0.39 for wider illumination
Fiber type
Multimode step-index
Standard for optogenetics (Sparta et al., 2012)
Ferrule diameter
1.25 mm (standard) or 2.5 mm
Compatibility with patch cables and commutators
Placement rule: Position the fiber tip 200-500 um above the target region to allow light cone to cover the structure while avoiding mechanical damage to the target itself (Yizhar et al., 2011).
Step 6: Control Conditions
A rigorous optogenetic experiment requires AT MINIMUM three of the following controls (Fenno et al., 2011):
Control
What It Rules Out
Implementation
Opsin-negative + light
Heating, visual, auditory artifacts from light
Inject control virus (e.g., AAV-hSyn-eYFP), deliver identical light
Opsin-positive + no light
Effects of viral expression alone
Implant fiber, run behavioral protocol without laser
Wavelength control
Non-specific photic effects
Deliver light at a wavelength outside the opsin's activation spectrum
Fiber implant only
Mechanical damage effects
Implant fiber without virus injection
Within-subject light-off epochs
Temporal confounds
Interleave light-on and light-off trials within sessions
The single most common critique of optogenetic studies is inadequate controls. The opsin-negative + light control is non-negotiable (Fenno et al., 2011).
Common Pitfalls and Domain-Specific Warnings
1. Depolarization Block (Silencing When You Intend to Activate)
At high ChR2 expression levels or with prolonged/high-frequency stimulation, excessive cation influx causes sustained depolarization that inactivates sodium channels, STOPPING action potentials (Herman et al., 2014; Lin et al., 2009). This is especially dangerous with interneurons, which enter depolarization block more readily than pyramidal cells.
Signs: Loss of spiking after initial pulses in a train; behavioral effect opposite to prediction.
Prevention: Limit pulse width to 1-5 ms; keep frequency at or below 40 Hz for ChR2; titrate expression levels; use ChETA for high-frequency applications.
2. Tissue Heating Artifacts
Continuous illumination at high power heats tissue, altering neuronal firing even without opsin expression (Owen et al., 2019; Christie et al., 2013). Blue light (473 nm) is worse than red (638 nm) for heating.
Prevention: Use pulsed (not continuous) light; keep duty cycle below 40% at moderate power; use temperature modeling (Stujenske et al., 2015); always include opsin-negative light controls.
3. Viral Expression Toxicity
High viral titers (>1e13 vg/mL) can cause cytotoxicity, especially with prolonged expression times (>8 weeks) (Miyashita et al., 2013). Overexpression of membrane proteins disrupts normal cell physiology.
Prevention: Use titers of 1e12 to 5e12 vg/mL for standard applications; check for cell health at the injection site post-mortem; limit expression time to 3-6 weeks for most applications.
4. Backpropagation of Light Along Fibers
Light can scatter back up the fiber and illuminate unintended brain regions above the target. This is especially problematic for superficial targets near the brain surface.
Prevention: Use opaque ferrule sleeves; verify illumination volume with computational modeling; consider tapered fibers for focal illumination.
5. Antidromic Activation with Axonal Opsins
When inhibitory opsins (especially GtACR2, not soma-targeted) are expressed in axons, blue light can cause depolarization at the axon initial segment, producing paradoxical excitation (Mahn et al., 2018).
Prevention: Use soma-targeted variants (stGtACR2) for inhibition; avoid illuminating axon terminals with anion channelrhodopsins; verify with electrophysiology.
6. Chloride Loading with Halorhodopsin
Prolonged eNpHR3.0 activation loads neurons with chloride, shifting the GABA-A reversal potential and causing rebound excitation upon light offset (Raimondo et al., 2012).
Prevention: Limit continuous NpHR activation to <15 seconds; use pulsed protocols for longer inhibition; consider anion channels (stGtACR2) for sustained inhibition.
Viral Vector Quick Reference
Serotype
Tropism
Onset
Spread
Use Case
AAV1
Broad neuronal
1-2 weeks
Large
General transduction (Aschauer et al., 2013)
AAV2
Neuronal (restricted)
2-4 weeks
Small
Precise local targeting
AAV5
Neurons + glia
2-4 weeks
Moderate
Use with neuron-specific promoter
AAV8
Broad neuronal
1-2 weeks
Large
Deep brain structures
AAV9
Broad, crosses BBB
1-2 weeks
Large
Systemic delivery, broad transduction
AAVrg
Retrograde neuronal
2-4 weeks
Projection-specific
Circuit-specific targeting (Tervo et al., 2016)
Always use a neuron-specific promoter (hSyn, CaMKII) with AAV1/5/8/9, as ubiquitous promoters (CMV, CAG) will also transduce glia (Aschauer et al., 2013).
Standard injection volume: 200-500 nL per site in mice; 1-2 uL per site in rats (Cetin et al., 2006).
Standard titer: 1e12 to 5e12 vg/mL (Miyashita et al., 2013).
Wait for expression: Minimum 2-3 weeks post-injection; optimal at 3-6 weeks for most AAVs.
Protocol Assembly Checklist
Before finalizing a protocol, verify:
Opsin matches the manipulation type (excitation/inhibition/bistable)
Wavelength matches the opsin's absorption spectrum (+/- 20 nm)
Power density is within the opsin's effective range but below heating threshold
Pulse frequency does not exceed the opsin's temporal fidelity
Duty cycle is below 40% for sustained protocols at moderate-to-high power
Fiber is positioned 200-500 um above target
At least opsin-negative + light control is planned
Viral titer is in the 1e12-5e12 vg/mL range
Expression time is 3-6 weeks (not <2 weeks, not >8 weeks without toxicity check)
Post-hoc histology is planned to verify expression and fiber placement
Key References
Aravanis, A. M. et al. (2007). An optical neural interface: in vivo control of rodent motor cortex. J. Neural Eng., 4(3), S143-S156.
Boyden, E. S. et al. (2005). Millisecond-timescale, genetically targeted optical control of neural activity. Nat. Neurosci., 8(9), 1263-1268.
Chow, B. Y. et al. (2010). High-performance genetically targetable optical neural silencing by light-driven proton pumps. Nature, 463, 98-102.
Deisseroth, K. (2015). Optogenetics: 10 years of microbial opsins in neuroscience. Nat. Neurosci., 18(9), 1213-1225.
Fenno, L., Yizhar, O. & Deisseroth, K. (2011). The development and application of optogenetics. Annu. Rev. Neurosci., 34, 389-412.
Gunaydin, L. A. et al. (2010). Ultrafast optogenetic control. Nat. Neurosci., 13(3), 387-392.
Hochbaum, D. R. et al. (2014). All-optical electrophysiology in mammalian neurons. Nat. Methods, 11, 825-833.
Klapoetke, N. C. et al. (2014). Independent optical excitation of distinct neural populations. Nat. Methods, 11, 338-346.
Mahn, M. et al. (2018). High-efficiency optogenetic silencing with soma-targeted anion-conducting channelrhodopsins. Nat. Commun., 9, 4125.
Marshel, J. H. et al. (2019). Cortical layer-specific critical dynamics triggering perception. Science, 365(6453), eaaw5202.
Mattis, J. et al. (2012). Principles for applying optogenetic tools derived from direct comparative analysis of microbial opsins. Nat. Methods, 9, 159-172.
Stujenske, J. M. et al. (2015). Modeling the spatiotemporal dynamics of light and heat propagation for in vivo optogenetics. Cell Rep., 12(3), 525-534.
Yizhar, O. et al. (2011). Optogenetics in neural systems. Neuron, 71(1), 9-34.
